REVA bags $42m from Medtronic et al:
This article was originally published in Clinica
San Diego, California-based REVA Medical has secured $42m to fund the development of its bioresorbable stents for the treatment of arterial disease. The funds were raised in a private financing round led by Cerberus Capital Management and Brookside Capital, and contributed to by new shareholders Medtronic and Pequot Management, along with existing investors Domain Partners and Group Outcome. REVA will use the proceeds to take its stents to clinical trials.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.